Craft
  • Home
  •  / MannKind Corporation
MannKind Corporation

MannKind Corporation

Patents Issued

1.02 K

FY, 2019

Revenue

$75.4 M

FY, 2021

Market Capitalization

$846.7 M

2022-09-20

MannKind Corporation Summary

Company summary

Overview
MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. The Company's lead product candidate, Afrezza, is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Afrezza is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream.
Type
Public
Founded
1991
HQ
Westlake Village, CA, US | view all locations
Website
http://www.mannkindcorp.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Michael Castagna

    Michael Castagna, Chief Executive Officer, Director

  • Ronald Consiglio, Director

    • Kent Kresa

      Kent Kresa, Chairman of the Board

      • Henry L. Nordhoff, Director

        Operating MetricsView all

        Patent Applications (Afrezza)

        125
        21.9%

        FY, 2019

        Patents Issued (Afrezza)

        600
        5.3%

        FY, 2019

        Patent Applications

        240
        14.3%

        FY, 2019

        LocationsView all

        2 locations detected

        • Westlake Village, CA HQ

          United States

          30930 Russell Ranch Rd #301

        • Danbury, CT

          United States

          1 Casper St

        MannKind Corporation Financials

        Summary financials

        Revenue (Q2, 2022)
        $18.9M
        Gross profit (Q2, 2022)
        $14.3M
        Net income (Q2, 2022)
        ($29.0M)
        Cash (Q2, 2022)
        $35.5M
        EBIT (Q2, 2022)
        ($20.5M)
        Enterprise value
        $1.1B

        Footer menu